摘要
目的 比较紫杉醇和长春瑞滨分别联合顺铂在非小细胞肺癌治疗中的近期疗效和毒副反应。方法 病人分成两组，NP组36例，NVB25mg／m^2，静滴d1，d8，DDP80-100mg／m^2，静滴d1-3；TP组38例，Paclitael 135-175mg／m^2，静滴，d1，DDP80-100mg／m^2，静滴d1-3；21-28d为一周期。结果 NP组总有效率（ORR）58.3％，TP组总有效率（ORR）63．1％。主要毒副反应为骨髓抑制，胃肠反应，浅表静脉炎，周围神经炎。结论 两组疗效无显著差异，毒副反应各有不同，化疗方案的选择以个体对毒副作用的耐受性为主要考虑因素。
Objective To compare clinical efficacy and toxicities of paclitaxel and vinorelbine combined with cisplatin in the treatment of non-small cell lung cancer （NACLC）. Methods The patients were divided into two groups （NP and TP）. Group NP was treated by vinorelbine 25mg/m^2, day1 and day 8, cisplatin 80-100 mg/m^2, divided day1-3, and to repeat every 3 weeks. Group TP was treated by, Pclitaxel 135-175 mg/m^2, day1-3, cisplatin 80-100mg/m^2, divided day1-3, and to repeat every 3 weeks. Results Both over response rate （ORR） were 58.3%（21/36） and 63.1%（24/38） in Group NP and TP, respectively. Major toxicities were hematological, digestive toxicities, phlebophlogosis, peripheral neuritis. Condusion The clinical efficacy of both groups exist no significance. Both toxicities are not the same. We should principally consider the individual tolerance to the toxicities, when we choice the chemotherapeutic policy.
出处
《世界肿瘤杂志》
2005年第4期284-285,共2页
Tumour Journal of the World
